Get the Stockscreener App
0.6357
26.24%
-0.2262
After Hours:
.61
-0.0257
-4.04%
Aptevo Therapeutics Inc stock is traded at $0.6357, with a volume of 56.87M.
It is down -26.24% in the last 24 hours and down -75.26% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$0.8619
Open:
$1.12
24h Volume:
56.87M
Relative Volume:
22.27
Market Cap:
$3.35M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.00654
EPS:
-97.2514
Net Cash Flow:
$-23.28M
1W Performance:
-38.88%
1M Performance:
-75.26%
6M Performance:
-92.81%
1Y Performance:
-97.64%
1-Day Range:
$0.6036
$1.35
1-Week Range:
$0.6036
$1.35
52-Week Range:
$0.6036
$51.06
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
0.6357 | 3.35M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Aptevo Therapeutics (APVO) Secures $2M Through Registered Direct Offering | APVO Stock News - GuruFocus
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | APVO Stock News - GuruFocus
Aptevo Therapeutics announces $2 million stock offering - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Aptevo Therapeutics Raises Fresh Capital: $2M Boost for Revolutionary Cancer Treatment Development - Stock Titan
Aptevo Therapeutics Inc (APVO) Stock: Navigating a Year of Volatility - investchronicle.com
How does APVO’s price to cash per share ratio compare in the market? - uspostnews.com
Aptevo Therapeutics (APVO) Completes $2.1 Million Stock Offering - GuruFocus
Why Netflix Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
APVO stock plunges to 52-week low, touches $0.94 By Investing.com - Investing.com South Africa
APVO stock plunges to 52-week low, touches $0.94 - Investing.com Australia
Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 - ACCESS Newswire
Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High - Asianet Newsable
Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Aptevo Secures Fresh $2.1M Capital: What This Means for Clinical Pipeline - Stock Titan
SEC Form 424B4 filed by Aptevo Therapeutics Inc. - Quantisnow
Strategic Moves Drive Stock Gains For OSR, Lianhe Sowell, And Aptevo - Finimize
Aptevo (APVO) Sees Significant Market Rally After Equity Offering - Stocks Telegraph
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Aptevo Therapeutics Launches $2.1 Million Registered Direct Offering; Shares Rise - MarketScreener
Aptevo Therapeutics (APVO) Announces $2.1 Million Securities Off - GuruFocus
Aptevo Therapeutics announces registered direct offering and warrants sale - Investing.com
Aptevo Therapeutics prices 1.76M shares at $1.19 in registered direct offering - TipRanks
Aptevo Raises Fresh Capital: $2.1M Direct Offering Plus Warrant Restructuring - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Why Penguin Solutions Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan - ACCESS Newswire
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
APVO stock plunges to 52-week low, touches $0.99 By Investing.com - Investing.com India
APVO stock plunges to 52-week low, touches $0.99 - Investing.com
Virtu Financial LLC Has $93,000 Stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) - Defense World
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Growth in Short Interest - Defense World
APVO stock plunges to 52-week low, touches $2.32 - Investing.com India
APVO stock plunges to 52-week low, touches $2.32 By Investing.com - Investing.com UK
Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment - Benzinga
Aptevo Therapeutics Reports 2 More Remissions in AML Trial -March 20, 2025 at 09:35 am EDT - Marketscreener.com
Aptevo Therapeutics Achieves Remission Success in AML Trial - TipRanks
Aptevo reports two additional AML patients achieve remission in RAINIER trial - TipRanks
Breakthrough: New AML Drug Shows 90% Success Rate, Outperforming Standard Therapy by 24% - StockTitan
Aptevo Therapeutics advances cancer antibody APVO603 in preclinical phase - Investing.com
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy - ACCESS Newswire
Breakthrough Cancer Drug APVO603 Targets Two Immune Pathways to Fight Solid Tumors - Stock Titan
Aptevo Therapeutics (NASDAQ:APVO) Raised to Sell at StockNews.com - Defense World
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Increase in Short Interest - Defense World
APVO stock plunges to 52-week low of $2.48 amid steep annual decline - Investing.com Australia
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):